Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 5, 2003, Pages 485-491

  Fynn, Simon P ^a   Todd, Derick M ^a   Hobbs, W Julian C ^a   Armstrong, Karen L ^a   Fitzpatrick, Adam P ^a   Garratt, Clifford J ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b Manchester Heart Centre   (United Kingdom)

Author keywords

Amiodarone; Atrial fibrillation; Atrial fibrillation cycle length; Cardioversion; Dispersion of atrial refractoriness

Indexed keywords

AMIODARONE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CORONARY SINUS; DRUG EFFICACY; ELECTROPHYSIOLOGY; FEMALE; HEART ATRIUM FIBRILLATION; HEART RIGHT ATRIUM; HEART VENTRICLE SEPTUM; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SINUS RHYTHM;

ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RECURRENCE; STATISTICS; THYROID FUNCTION TESTS; TREATMENT OUTCOME;

EID: 0038242278     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02388.x     Document Type: Article

References (39)

1. Van Gelder IC, Crijns HJ, van Gilst WH, Verwer R, Lie KI: Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-46.
2. Moe GK, Rheinboldt WC, Abildskov JA: A computer model of atrial fibrillation. Am Heart J 1964;67:200-220.
3. Allessie MA, Lammers WJEP, Bonke FIM, Hollen SJ: Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton, 1985, pp. 265-275.
4. Fynn SP, Todd DM, Hobbs WJC, Armstrong KL, Garratt CJ: Role of dispersion of atrial refractoriness in the recurrence of clinical atrial fibrillation. A manifestation of atrial electrical remodelling in humans? Eur Heart J 2001:22;1822-1834.
5. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920.
6. Fynn SP, Todd DM, Hobbs WJC, Armstrong KL, Fitzpatrick AP, Garratt CJ: Clinical evaluation of a policy of early repeated internal cardioversion for recurrence of atrial fibrillation. J Cardiovasc Electrophysiol 2002;13:135-141.
7. Hartel G, Louhija A, Konttinen A: Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 1974;15:551-555.
8. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
9. Juul MS, Edvardsson N, Rehnqvist AN: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
10. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA: Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146.
11. Van Gelder IC, Crijns HJ, van Gilst WH, Van Wijk LM, Hamer HP, Lie KI: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
12. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011.
13. De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, De Matteis C, Rotunno R, Di Napoli T: Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-814.
14. Gosselink AT, Crijns HJ, van Gelder IC, Hillige H, Wiesfeld AC, Lie KI: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
15. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauf HR, Singh BN: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
16. O'Keefe DB, Nicholls DP, Morton P, Murtach GH, Scott ME: Maintenance of sinus rhythm after elective cardioversion from chronic stable atrial fibrillation amiodarone compared with quinidine. Br Heart J 1984;5:103-104.
17. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-998.
18. Kochiadakis GE, Igoumenidis NE, Marketou ME, Skaladis EI, Kaleboubas MD, Mavrakis HE: Low-dose amiodarone in the treatment of recurrent symptomatic atrial fibrillation: A placebo-controlled study. (Abstract) J Am Coll Cardiol 2000;118A.
19. Fareh S, Villemaire C, Nattel S: Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998;98:2202-2209.
20. Gaspo R, Bosch RF, Talajic M, Nattel S: Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997;96:4027-4035.
21. Wang J, Liu L, Feng J, Nattel S: Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol 1996;273(Heart Circ Physiol 40):H148-H158.
22. Lui L, Nattel S: Differing sympathetic and vagal effects of atrial fibrillation in dogs: Role of refractoriness heterogeneity. Am J Physiol 1997;273 (Heart Circ Physiol 42):H805-H816.
23. Satoh T, Zipes DP: Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:833-842.
24. Boutjdir M, Le Heuzey JY, Lavergne T, Chauvaud S, Guise L, Carpentier A, Peronneau P: Inhomogeneity of cellular refractoriness in human atrium: Factor of arrhythmia? Pacing Clin Electrophysiol 1986;9:1095-1100.
25. Ramanna H, Hauer RN, Wittkampf FH, de Bakker JM, Wever EF, Elvan A, Robles De Medina EO: Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation. Circulation 2000;101:995-1101.
26. Ramdat Misier A, Opthof T, van Hemel NM, Defauw JJAM, De Bakker JMT, Janse MJ, van Capelle FJL: Increased dispersion of "refractoriness" in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992;19:1531-1535.
27. Waxman HL, Groh WC, Marchlinski FE, Buxton AE, Sadowski LM, Horowitz LN, Josephson ME, Kastor JA: Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients. Am J Cardiol 1982;50:1066-1074.
28. Rosen MR, Wit AL: Electropharmacology of antiarrhythmic drugs. Am Heart J 1983;106:829-839.
29. Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP: Amiodarone: Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 1981;305:539-545.
30. Balser JR, Bennett PB, Hondeghem LM, Roden DM: Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res 1991;69:519-529.
31. Mason JW, Hondeghem LM, Katzung BG: Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res 1984;55:277-285.
32. Charlier R: Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 1970;39:668-674.
33. Nattel S, Talajic M, Quantz M. DeRoode M: Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: Evidence for calcium-channel blocking activity. Circulation 1987;76:442-449.
34. Ayers GM, Rho TH, Ben-David J, Besch HRJ, Zipes DP: Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:713-721.
35. Wirth KJ, Knobloch K: Differential effects of dofetilide, amiodarone, and class 1c drugs on left and right atrial refractoriness and left atrial vulnerability in pigs. Naunyn-Schmiedebergs Arch Pharmacol 2001;363:166-174.
36. Wijffels MCEF, Dorland R, Mast F, Allessie MA: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat. Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000;102:260-267.
37. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M: Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-3163.
38. Shinagawa K, Mitamura H, Takeshita A, Sato T, Kanki H, Takatsuki S, Ogawa S: Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: Direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol 2000;35:246-253.
39. Nattel S, Bourne G, Talajic M: Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol 1997;8:469-480.